Applications of magnetic nanoparticles in biomedicine

Nanoscale Magnetic Materials and Applications

Volumn , Issue , 2009, Pages 591-626

  Bárcena, Carlos ^a,b   Sra, Amandeep K ^a   Gao, Jinming ^a,b  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b UNIVERSITY OF TEXAS AT DALLAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 79960080109     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-0-387-85600-1_20     Document Type: Chapter

References (216)

1. Ai, H., et al.: Magnetite-loaded polymeric micelles as ultrasensitive magnetic-resonance probes. Adv. Mater. 17, 1949-1952 (2005).
2. Albregts, M., et al.: A feasibility study in oesophageal carcinoma using deep loco-regional hyperthermia combined with concurrent chemotherapy followed by surgery. Int. J. Hyperthermia 20, 647-659 (2004).
3. Alexiou, C., et al.: Locoregional cancer treatment with magnetic drug targeting. Cancer Res. 60, 6641-6648 (2000).
4. Alexiou, C., et al.: Magnetic drug targeting: biodistribution and dependency on magnetic field strength. J. Magn. Magn. Mater. 252, 363-366 (2002).
5. Alexiou, C., et al.: In vitro and in vivo investigations of targeted chemotherapy with magnetic nanoparticles. J. Magn. Magn. Mater. 293, 389-393 (2005).
6. Alvarez Secord, A., et al.: Phase I/II trial of intravenous Doxil R and whole abdomen hyperthermia in patients with refractory ovarian cancer. Int. J. Hyperthermia 21, 333-347 (2005).
7. Amsalem, Y., et al.: Iron-oxide labeling and outcome of transplanted mesenchymal stem cells in the infarcted myocardium. Circulation 116(suppl. I), I38-I45 (2007).
8. Anastase, S., et al.: Affinity chromatography of human anti-dextran antibodies: isolation of two distinct populations. J. Chromatogr. B, Biomed. Sci. Appl. 686, 141-150 (1996).
9. Anderson, S.A., et al.: Noninvasive MR imaging of magnetically labeled stem cells to directly identify neovasculature in a glioma model. Blood 105, 420-425 (2005).
10. Anzai, Y., et al.: Initial clinical experience with dextran-coated superparamagnetic iron oxide for detection of lymph node metastases in patients with head and neck cancer. Radiology 192, 709-715 (1994).
11. Anzai, Y., et al.: Initial clinical experience with dextran-coated superparamagnetic iron oxide for detection of lymph node metastases in patients with head and neck cancer. J. Magn. Reson. Imaging 7, 75-81 (1997).
12. Anzai, Y., et al.: Evaluation of neck and body metastases to nodes with ferumoxtran 10- enhanced MR imaging: phase III safety and ffficacy study. Radiology 228, 777-788 (2003).
13. Arbab, A.S., et al.: Ferumoxides-enhanced double-echo T2-weighted MR imaging in differentiating metastases from nonsolid benign lesions of the liver. Radiology 225, 151-158 (2002).
14. Arbab, A.S., et al.: Characterization of biophysical and metabolic properties of cells labeled with superparamagnetic iron oxide nanoparticles and transfection agent for cellular MR imaging. Radiology 229, 838-846 (2003).
15. Arbab, A.S., et al.: In vivo trafficking and targeted delivery of magnetically labelled stem cells. Hum. Gene Ther. 15, 351-360 (2004).
16. Arbab, A.S., et al.: Comparison of transfection agents in forming complexes with ferumoxides, cell labeling efficiency, and cellular viability. Mol. Imag. 3, 24-32 (2004).
17. Arbab, A.S., et al.: Labeling of cells with ferumoxides-protamine sulfate complexes does not inhibit function or differentiation capacity of hematopoietic or mesenchymal stem cells. NMR Biomed. 18, 553-559 (2005).
18. Arbab, A.S., et al.: Labeled endothelial progenitor cells trafficking to sites of tumor angiogenesis magnetic resonance imaging and confocal microscopy studies of magnetically. Stem Cells 24, 671-678 (2006).
19. Arruebo, M., et al.: Antibody-functionalized hybrid superparamagnetic nanoparticles. Adv. Funct. Mater. 17, 1473-1479 (2007).
20. Artemov, D., et al.: MR molecular imaging of the Her-2/neu receptor in breast cancer cells using targeted iron oxide nanoparticles. Magn. Reson. Med. 49, 403-408 (2003).
21. Artemov, D., et al.:Magnetic resonance molecular imaging of the HER-2/neu receptor. Cancer Res. 63, 2723-2727 (2003).
22. Babes, L., et al.: Synthesis of iron oxide nanoparticles used as MRI contrast agents: A parametric study. J. Colloid Interface Sci. 212, 474-482 (1999).
23. Bach-Gansmo, T.: Ferrimagnetic susceptibility contrast agents. Acta Radiol. Suppl. 387, 1-30 (1993).
24. Bach-Gansmo, T., et al.: Abdominal MRI using a negative contrast agent. Br. J. Radiol. 66, 420-425 (1993).
25. Bayer HealthCare Pharmaceuticals: Feridex R . http://imaging. bayerhealthcare.com/html/feridex/index.html(2007. Accessed 5 November 2007.
26. Bee, A., et al.: Synthesis of very fine maghemite particles. J. Magn. Magn. Mater. 149, 6-9 (1995).
27. 3 vacancies ordering and lattice parameters. J. Solid State Chem. 163, 459-465 (2002).
28. Ben-Hur, T., et al.: Serial in vivo MR tracking of magnetically labeled neural spheres transplanted in chronic EAE mice. Magn. Reson. Med. 57, 164-171 (2007).
29. 2 effects in vivo and ex vivo using iron oxide nanoparticles in steady state-dependence on blood volume and water exchange. Magn. Reson. Med. 47, 461-471 (2002).
30. Bonnemain, B.: Superparamagnetic agents in magnetic resonance imaging. Physicochemical characteristics and clinical application. A review. J. Drug Target. 6, 167-174 (1998).
31. Bos, C. et al.: In vivo MR imaging of intravascularly injected magnetically labeled stem cells in rat kidney and liver. Radiology 233, 781-789 (2004).
32. Boudghëne, F.P., et al.: Contribution of oral magnetic particles in MR imaging of the abdomen with spin-echo and gradient-echo sequences. J. Magn. Reson. Imaging 3, 107-112 (1993).
33. Brusentsov, N.A., et al.: Evaluation of ferromagnetic fluids and suspensions for the sitespecific radiofrequency-induced hyperthermia of MX11 sarcoma cells in vitro. J. Magn. Magn. Mater. 225, 113-117 (2001).
34. Bulte, J.W.M., et al.: Neurotransplantation of magnetically labeled oligodendrocytes progenitors: magnetic resonance tracking of cell migration and myelination. Proc. Natl. Acad. Sci. 96, 15256-15261 (1999).
35. Bulte, J.W.M. and Kraitchman, D.L.: Iron oxide MR contrast agents for molecular and cellular imaging. NMR Biomed. 17, 484-499 (2004).
36. Butle, J.W., et al.: Specific MR imaging of human lymphocytes by monoclonal antibodyguided dextran-magnetite particles. Magn. Reson. Med. 25, 148-157 (1992).
37. Cahill, K.S., et al.: Noninvasive monitoring and tracking of muscle stem cell transplant. Transplantation 78, 1626-1633 (2004).
38. Carreño, T.G., et al.: Preparation of homogeneous Zn/Co mixed oxides by spray pyrolysis. Mater. Chem. Phys. 27, 287-296 (1991).
39. Cerdan, S., et al.: Monoclonal antibody-coated magnetite particles as contrast agents in magnetic resonance imaging of tumors. Magn. Reson. Med. 12, 151-163 (1989).
40. 4 nanoparticles and their biomedical applications. Biomaterials 26, 729-738 (2005).
41. Choi, H.S., et al.: Renal clearance of quantum dots. Nat. Biotechnol. 25, 1165-1170 (2007).
42. Choi, J.-S., et al.: Biocompatible heterostructured nanoparticles for multimodal biological detection. J. Am. Chem. Soc. 128, 15982-15983 (2006).
43. Corot, C., et al.: Recent advances in iron oxide nanocrystal technology for medical imaging. Adv. Drug Del. Rev. 58, 1471-1504 (2006).
44. Daldrup-Link, H.E., et al.: Macromolecular contrast medium (Feruglose) versus small molecular contrast medium (Gadopentetate) enhanced magnetic resonance imaging: differentiation of benign and malignant breast lesions. Acad. Radiol. 10, 1237-1246 (2003).
45. Damadian, R.: Tumor detection by nuclear magnetic resonance. Science 171, 1151-1153 (1971).
46. Damadian, R.: Apparatus and method for detecting cancer in tissue. US Patent 3, 789, 832: February 5, 1974.
47. Dandamudi, S. and Campbell, R.B.: The drug loading, cytotoxicty and tumor vascular targeting characteristics of magnetite in magnetic drug targeting. Biomaterials 28, 4673-4683 (2007).
48. Decher, G.: Fuzzy nanoassemblies: Toward layered polymeric multicomposites. Science 277, 1232-1237 (1997).
49. Deng, Y., et al.: Preparation of magnetic polymeric particles via inverse microemulsion polymerization process. J. Magn. Magn. Mater. 257, 69-78 (2003).
50. Duterloo, H.S.: Historic publication on the first use of magnets in orthodontics. Am. J. Orthod. Dentofacial Orthop. 108, 15A-16A (1995).
51. Dutton, A.H., et al.: Iron-dextran antibody conjugates: general method for simultaneous staining of two components in high-resolution immunoelectron microscopy. Proc. Natl. Acad. Sci. 76, 3392-3396 (1979).
52. Fajardo, L.F.: Pathological effects of hyperthermia in normal tissues. Cancer Res. 44(suppl.), 4826s-4835s (1984).
53. Fauconnier, N., et al.: Thiolation of maghemite nanoparticles by dimercaptosuccinic acid. J. Colloid Interface Sci. 194, 427-433 (1997).
54. Fishbane, S., et al.: The safety of intravenous iron dextran in hemodialysis patients. Am. J. Kidney Dis. 28, 529-534 (1996).
55. Forbes, Z.G., et al.: An approach to targeted drug delivery based on uniform magnetic fields. IEEE Trans. Magn. 39, 3372-3377 (2003).
56. Funovics, M.A., et al.: MR imaging of the her2/neu and 9.2.27 tumor antigens using immunospecific contrast agents. Magn. Reson. Imaging 22, 843-850 (2004).
57. Gallo, J.M., et al.: Targeting anticancer drugs to the brain: II. Physiological pharmacokinetic model of oxantrazole following intraarterial administration to rat glioma-2 (RG-2) bearing rats. J. Pharmacokin. Biopharm. 21, 575-592 (1993).
58. Gittins, D.I. and Caruso, F.: Spontaneous phase transfer of nanoparticulate metals from organic to aqueous media. Angew. Chem. Int. Ed. 40, 3001-3004 (2001).
59. Glockl, G., et al.: The effect of field parameters, nanoparticle properties and immobilization on the specific heating power in magnetic particle hyperthermia. J. Phys.: Condens. Matter 18, S2935-S2949 (2006).
60. Gomi, T., et al.: Evaluation of the changes in signals from the spleen using ferucarbotran. Radiat. Med. 25, 135-138 (2007).
61. Goya, F.G., et al.: Static and dymanic magnetic properties of spherical magnetite nanoparticles. J. Appl. Phys. 94, 3520-3528 (2003).
62. Grief, A.D. and Richardson, G.: Mathematical modelling of magnetically targeted drug delivery. J. Magn. Magn. Mater. 293, 455-463 (2005).
63. Groman, E.V.: Biologically degradable superparamagnetic materials for use in clinical applications. US Patent 4, 827, 945: May 9, 1989.
64. Gupta, A.K. and Wells, S.: Surface-modified superparamagnetic nanoparticles for drug delivery: preparation, characterization, and cytotoxicity. IEEE Trans. Nanobiosci. 3, 66-73 (2004).
65. Gupta, A.K. and Curtis, A.S.G.: Surface modified superparamagnetic nanoparticles for drug delivery: interaction studies with human fibroblasts in culture. J. Mater. Sci.: Mater. Med. 15, 493-496 (2004).
66. Gupta, A.K. and Gupta, M.: Cytotoxicity suppression and cellular uptake enhancement of surface modified magnetic nanoparticles. Biomaterials 26, 1565-1573 (2005).
67. Gupta, A.K. and Gupta, M.: Synthesis and surface engineering of iron oxide nanoparticles for biomedical applications. Biomaterials 26, 3995-4021 (2005).
68. Guzman, R., et al.: Long-term monitoring of transplanted human neural stem cells in developmental and pathological contexts with MRI. Proc. Natl. Acad. Sci. 104, 10211-10216 (2007).
69. Häfeli, U.: The History of Magnetism in Medicine. In: Andrä, W. and Nowak, H. (eds.) Magnetism in Medicine: A Handbook, Second Edition, pp. 1-25.Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim (2007).
70. Hahn, P.F., et al.: First clinical trials of a new superparamagnetic iron oxide for the use as an oral gastrointestinal contrast agent in MR imaging. Radiology 175, 695-700 (1990).
71. Harisinghani, M.G., et al.: Splenic imaging with ultrasmall superparamagnetic iron oxide ferumoxtran-10 (AMI-7227): preliminary observations. J. Comput. Assist. Tomogr. 25, 770- 776 (2001).
72. Harisinghani, M.G., et al.: Noninvasive detection of clinically occult lymph-node metastases in prostate cancer. N. Engl. J. Med. 348, 2491-2499 (2003).
73. Hasegawa, M. and Hokkoku, S.: Magnetic iron oxide-dextran complex and process for its production. US Patent 4, 101, 435: July 18, 1978.
74. Hergt, R., et al.: Magnetic particle hyperthermia: nanoparticle magnetism and materials development for cancer therapy. J. Phys.: Condens. Matter 18, S2919-S2934 (2006).
75. Hill, J.M., et al.: Serial cardiac magnetic resonance imaging of injected mesenchymal stem cells. Circulation 108, 1009-1014 (2003).
76. Himes, N., et al.: In vivo MRI of embryonic stem cells in a mouse model of myocardial infarction. Magn. Reson. Med. 52, 1214-1219 (2004).
77. Hogemann, D., et al.: High throughput magnetic resonance imaging for evaluating targeted nanoparticle probes. Bioconjug. Chem. 13, 116-121 (2002).
78. 4 nanoparticles. China Particuology 5, 186-191 (2007).
79. Hu, D.E., et al.: Monitoring T-lymphocyte trafficking in tumors undergoing immune rejection. Magn. Reson. Med. 54, 1473-1479 (2005).
80. Hyeon, T., et al.: Synthesis of highly crystalline and monodisperse maghemite nanocrystallites without a size-selection process. J. Am. Chem. Soc. 123, 12798-12801 (2001).
81. Hyeon, T., et al.: Synthesis of highly crystalline and monodisperse cobalt ferrite nanocrystals J. Phys. Chem. B 106, 6831-6833 (2002).
82. Ichikawa, T., et al.: MRI of transgene expression: correlation to therapeutic gene expression. Neoplasia 4, 523-530 (2002).
83. Igartua, M., et al.: Development and characterization of solid lipid nanoparticles loaded with magnetite. Int. J. Pharm. 233, 149-157 (2002).
84. Ittrich, H., et al.: In vivo magnetic resonance imaging of iron oxide-labeled, arteriallyinjected mesenchymal stem cells in kidneys of rats with acute ischemic kidney injury: detection and monitoring at 3T. J. Magn. Reson. Imag. 25, 1179-1191 (2007).
85. Jacobsen, T.F., et al.: Oral magnetic particles (ferristene) as a contrast medium in abdominal magnetic resonance imaging. Acad. Radiol. 3, 571-580 (1996).
86. Jendelova, P., et al.: Magnetic resonance tracking of transplanted bone marrow and embryonic stem cells labeled by iron oxide nanoparticles in rat brain and spinal cord. J. Neurosci. Res. 76, 232-243 (2004).
87. Johannsen, M., et al.: Clinical hyperthermia of prostate cancer using magnetic nanoparticles: presentation of a new interstitial technique. Int. J. Hyperthermia 21, 637-647 (2005).
88. Johansson, L.O., et al.: A targeted contrast agent for magnetic resonance imaging of thrombus: implications of spatial resolution. J. Magn. Reson. Imaging 13, 615-618 (2001).
89. Josephson, L., et al.: High-efficiency intracellular magnetic labeling with novel superparamagnetic-tat peptide conjugates. Bioconjug. Chem. 10, 186-191 (1999).
90. Ju, S., et al.: In Vivo MR tracking of mesenchymal stem cells in rat liver after intrasplenic transplantation. Radiology 245, 206-215 (2007).
91. Jun, Y.-W., et al.: Nanoscale size effect of magnetic nanocrystals and their utilization for cancer diagnosis via magnetic resonance imaging. J. Am. Chem. Soc. 127, 5732-5733 (2005).
92. Jung, C.W. and Jacobs, P.: Physical and chemical properties of superparamagnetic iron oxide MR contrast agents: ferumoxides, ferumoxtran, ferumoxsil.Magn. Reson. Imaging 13, 661- 674 (1995).
93. Jurgons, R., et al.: Drug loaded magnetic nanoparticles for cancer therapy. J. Phys.: Condens. Matter 18, S2893-S2902 (2006).
94. Kanematsu, M., et al.: Imaging liver metastases: review and update. Eur. J. Radiol. 58, 217- 228 (2006).
95. Kang, E., et al.: Direct synthesis of highly crystalline and monodisperse manganese ferrite nanocrystals. J. Phys. Chem. B 108, 13932-13935 (2004).
96. Kang, H.W., et al.:Magnetic resonance imaging of inducible E-selectin expression in human endothelial cell culture. Bioconjug. Chem. 13, 122-127 (2002).
97. 3 particles. Chem. Mater. 8, 2209-2211 (1996).
98. Kato, H., et al.: Ferumoxide-enhanced MR imaging of hepatocellular carcinoma: correlation with histologic tumor grade and tumor vascularity. J. Magn. Reson. Imaging 19, 76-81 (2004).
99. Kehagias, D.T., et al.: Diagnostic efficacy and safety of MRI of the liver with superparamagnetic iron oxide particles (SH U 555 A). J. Magn. Reson. Imaging 14, 595-601 (2001).
100. Kelly, K.A., et al.: Detection of vascular adhesion molecule-1 expression using a novel multimodal nanoparticle. Circ. Res. 96, 327-336 (2005).
101. Kim, D.K., et al.: Synthesis and characterization of surfactant-coated superparamagnetic monodispersed iron oxide nanoparticles. J. Magn. Magn. Mater. 225, 30-36 (2001).
102. 4 nanocomposite powders for the separation and purification of biomolecules. Mater. Sci. Eng. A 449-451, 386-388 (2007).
103. Kim, Y.K., et al.: Detection of liver metastases: gadobenate dimeglumine-enhanced threedimensional dynamic phases and one-hour delayed phase MR imaging versus superparamagnetic iron oxide-enhanced MR imaging. Eur. Radiol. 15, 220-228 (2005).
104. Kircher, M.F., et al.: In vivo high resolution three-dimensional imaging of antigen-specific cytotoxic T-lymphocyte trafficking to tumors. Cancer Res. 63, 6838-6846 (2003).
105. Koh, D.-M., et al.: New horizons in oncologic imaging. N. Engl. J. Med. 348, 2487-2488 (2003).
106. Kopp, A., et al.: MR imaging of the liver with resovist: safety, efficacy, and pharmacodynamic properties. Radiology 204, 749-756 (1997).
107. Kraitchman, D.L., et al.: In vivo magnetic resonance imaging of mesenchymal stem cells in myocardial infarction. Circulation 107, 2290-2293 (2003).
108. Kresse, M., et al.: Targeting of ultrasmall superparamagnetic iron oxide (USPIO) particles to tumor cells in vivo by using transferrin receptor pathways. Magn. Reson. Med. 40, 236-242 (1998).
109. Kullberg, M., et al.: Improved drug delivery to cancer cells: A method using magnetoliposomes that target epidermal growth factor receptors. Med. Hypoth. 64, 468-470 (2005).
110. Laghi, A., et al.: Oral contrast agents for magnetic resonance imaging of the bowel. Top. Magn. Reson. Imaging 13, 389-396 (2002).
111. Lawaczeck, R., et al.: Superparamagnetic iron oxide particles: contrast media for magnetic resonance imaging. Appl. Organometal. Chem. 18, 506-513 (2004).
112. Lee, H., et al.: Thermally cross-linked superparamagnetic iron oxide nanoparticles: synthesis and application as a dual imaging probe for cancer in vivo. J. Am. Chem. Soc. 129, 12739- 12745 (2007).
113. Lee, J.-H., et al.: Dual-mode nanoparticle probes for high-performance magnetic resonance and fluorescence imaging of neuroblastoma. Angew. Chem. Int. Ed. 45, 8160-8162 (2006).
114. Lee, J.-H., et al.: Artificially engineered magnetic nanoparticles for ultra-sensitive molecular imaging. Nat. Med. 13, 95-99 (2007).
115. Lee, S.-J., et al.: Synthesis and characterization of superparamagnetic maghemite nanoparticles prepared by coprecipitation technique. J. Magn. Magn. Mater. 282, 147-150 (2004).
116. Lee, Y., et al.: Large-scale synthesis of uniform and crystalline magnetite nanoparticles using reverse micelles as nanoreactors under reflux conditions. Adv. Funct. Mater. 15, 503-509 (2005).
117. Lefebure, S., et al.: Monodisperse magnetic nanoparticles: preparation and dispersion in water and oils. J. Mater. Res. 13, 2975-2981 (1998).
118. Lemke, A.-J., et al.: MRI after magnetic drug targeting in patients with advanced solidmalignant tumors. Eur. Radiol. 14, 1949-1955 (2004).
119. Lewin, M., et al.: Tat peptide-derivatized magnetic nanoparticles allow in vivo tracking and recovery of progenitor cells. Nat. Biotechnol. 18, 410-414 (2000).
120. Li, S., et al.: Structured materials syntheses in a self-assembled surfactant mesophase. Colloids Surf. A 174, 275-281 (2000).
121. Livesay, B.R.: 9th International Conference on rare earth magnets and their applications. (1987).
122. 3 small particles prepared by spray pyrolysis. J. Magn. Magn. Mater. 140-144, 383-384 (1995).
123. Lübbe, A.S., et al.: Clinical applications of magnetic drug targeting. J. Surg. Res. 95, 200- 206 (2001).
124. MacVicar, D., et al.: Phase III trial of oral magnetic particles in MRI of abdomen and pelvis. Clin. Radiol. 47, 183-188 (1993).
125. Matuszewski, L., et al.: Cell tagging with clinically approved iron oxides: feasibility and effect of lipofection, particle size, and surface coating on labeling efficiency. Radiology 235, 155-161 (2005).
126. McLachlan, S.J., et al.: Phase I clinical evaluation of a new iron oxide MR contrast agent. J. Magn. Reson. Imaging 43, 301-307 (1994).
127. Metz, S., et al.: Capacity of human monocytes to phagocytose approved iron oxide MR contrast agents in vitro. Eur. Radiol. 14, 1851-1858 (2004).
128. Moore, A., et al.: Measuring transferrin receptor gene expression by NMR imaging. Biochim. Biophys. Acta 1402, 239-249 (1998).
129. Moore, A., et al.: In vivo targeting of underglycosylated MUC-1 tumor antigen using a multimodal imaging probe. Cancer Res. 64, 1821-1827 (2004).
130. Mykhaylyk, O., et al.: Doxorubicin magnetic conjugate targeting upon intravenous injection into mice: high gradient magnetic field inhibits the clearance of nanoparticles from the blood. J. Magn. Magn. Mater. 293, 473-482 (2005).
131. Namkung, S., et al.: Superparamagnetic iron oxide (SPIO)-enhanced liver MRI with ferucarbotran: efficacy for characterization of focal liver lesions. J. Magn. Reson. Imaging 25, 755-765 (2007).
132. Nedkov, I., et al.: Surface oxidation, size and shape of nano-sized magnetite obtained by co-precipitation. J. Magn. Magn. Mater. 300, 358-367 (2006).
133. Nishijima, S., et al.: A study on magnetically targeted drug delivery system using superconducting magnet. Physica C 463-465, 1311-1314 (2007).
134. Nishimura, H., et al.: Preoperative esophageal cancer staging: magnetic resonance imaging of lymph node with ferumoxtran-10, an ultrasmall superparamagnetic iron oxide. J. Am. Coll. Surg. 202, 604-611 (2006).
135. Oude Engberink, R.D., et al.: Comparison of SPIO and USPIO for in vitro labeling of human monocytes: MR detection and cell function. Radiology 243, 467-474 (2007).
136. Papell, S.S.: Low viscosity magnetic fluid obtained by the colloidal suspension of magnetic particles. US Patent 3, 215, 572: November 2, 1965.
137. Park, H.-Y., et al.: Fabrication of magnetic core@shell Fe oxide@Au nanoparticles for interfacial bioactivity and bio-separation. Langmuir 23, 9050-9056 (2007).
138. Park, J., et al.: Ultra-large-scale syntheses of monodisperse nanocrystals. Nat. Mater. 3, 891- 895 (2004).
139. Park, J., et al.: One-nanometer-scale size-controlled synthesis of monodisperse magnetic iron oxide nanoparticles. Angew. Chem. Int. Ed. 44, 2872-2877 (2005).
140. Pellegrino, T., et al.: Hydrophobic nanocrystals coated with an amphiphilic polymer shell: A general route to water soluble nanocrystals. Nano Lett. 4, 703-707 (2004).
141. Pillai, V., et al.: Preparation of nanoparticles of silver halides, superconductors and magnetic materials using water-in-oil microemulsions as nano-reactors. Adv. Colloid Interface Sci. 55, 241-269 (1995).
142. Pirko, I., et al.: In vivo magnetic resonance imaging of immune cells in the central nervous system with superparamagnetic antibodies. FASEB 18, 179-181 (2004).
143. Qin, J., et al.: A high-performance magnetic resonance imaging T2 contrast agent. Adv. Mater. 19, 1874-1878 (2007).
144. Raaphorst, G.P.: Fundamental aspects of hyperthermic biology. In: Field, S.B. and Hand, J.W. (eds.) An Introduction to the Practical Aspects of Clinical Hyperthermia, pp. 10-54. Taylor and Francis, London (1990).
145. Rad, A.M., et al.: Quantification of superparamagnetic iron oxide (SPIO)-labeled cells using MRI. J. Magn. Reson. Imag. 26, 366-374 (2007).
146. Reimer, P., et al.: Receptor imaging: Application to MR imaging of liver cancer. Radiology 177, 729-734 (1990).
147. Reimer, P. et al.: Receptor-directed contrast agents for MR imaging: preclinical evaluation with affinity assays. Radiology 182, 565-569 (1992).
148. Reimer, P., et al.: Pancreatic receptors: initial feasibility studies with a targeted contrast agent for MR imaging. Radiology 193, 527-531 (1994).
149. Reimer, P. and Tombach, B.: HepaticMRI with SPIO: detection and characterization of focal liver lesions. Eur. Radiol. 8, 1198-1204 (1998).
150. Reimer, P. and Balzer, T.: Ferucarbotran (Resovist): A new clinically approved RES-specific contrast agent for contrast-enhanced MRI of the liver: properties, clinical development, and applications. Eur. Radiol. 13, 1266-1276 (2003).
151. Remsen, L.G., et al.: MR of carcinoma-specific monoclonal antibody conjugated to monocrystalline iron oxide nanoparticles: The potential for noninvasive diagnosis. Am. J. Neuroradiol. 17, 411-418 (1996).
152. Renshaw, P.F., et al.: Immunospecific NMR contrast agents. Magn. Reson. Imaging 4, 351- 357 (1986).
153. Ritter, J.A., et al.: Application of high gradient magnetic separation principles to magnetic drug targeting. J. Magn. Magn. Mater. 280, 184-201 (2004).
154. Rockenberger, J., et al.: A new nonhydrolytic single-precursor approach to surfactant-capped nanocrystals of transition metal oxides. J. Am. Chem. Soc. 121, 11595-11596 (1999).
155. Roger, J., et al.: Behavior of aqueous ferrofluids in presence of amino acids. Eur. J. Solid State Inorg. Chem. 26, 475-488 (1989).
156. Rohrer, M., et al.: Comparison of magnetic properties of MRI contrast media solutions at different magnetic field strengths. Invest. Radiol. 40, 715-724 (2005).
157. Rudge, S.R., et al.: Preparation, characterization, and performance of magnetic iron-carbon composite microparticles for chemotherapy. Biomaterials 21, 1411-1420 (2000).
158. Sanderson, C.J. and Wilson, D.V.: A simple method for coupling proteins to insoluble polysaccharides. Immunology 20, 1061-1065 (1971).
159. Savellano, M.D. and Hasan, T.: Targeting cells that overexpress the epidermal growth factor receptor with polyethylene glycolated BPD verteporfin photosensitizer immunoconjugates. Photochem. Photobiol. 77, 431-439 (2003).
160. Schellenberger, E.A., et al.: Surface-functionalized nanoparticle library yields probes for apoptotic cells. Chem. Bio. Chem. 5, 275-279 (2004).
161. Schulze, E., et al.: Cellular uptake and trafficking of a prototypical magnetic iron oxide label in vitro. Invest. Radiol. 30, 604-610 (1995).
162. Seip, C.T., et al.: Magnetic properties of a series of ferrite nanoparticles synthesized in reverse micelles. IEEE Trans. Magn. 34, 1111-1113 (1998).
163. Semelka, R.C. and Helmberger, T.K.: Contrast agents forMR imaging of the liver. Radiology 218, 27-38 (2001).
164. Seo, W.S., et al.: FeCo/graphitic-shell nanocrystals as advanced magnetic-resonanceimaging and near-infrared agents. Nat. Mater. 5, 971-976 (2006).
165. Shen, T., et al.: Monocrystalline iron oxide nanocompounds (MION): physicochemical properties. MRM 29, 599-604 (1993).
166. Shen, T.T., et al.: Magnetically labeled secretin retains receptor affinity to pancreas acinar cells. Bioconjug. Chem. 7, 311-316 (1996).
167. Simon, G.H., et al.: Ultrasmall supraparamagnetic iron oxide-enhanced magnetic resonance imaging of antigen-induced arthritis. A comparative study between SHU 555 C, Ferumoxtran-10, and Ferumoxytol. Invest. Radiol. 41, 45-51 (2006).
168. Sminia, P., et al.: Effect of hyperthermia on the central nervous system. Int. J. Hyperthermia 10, 1-130 (1994).
169. Stark, D.D., et al.: Superparamagnetic iron oxide: clinical application as a contrast agent for MR imaging of the liver. Radiology 168, 297-301 (1988).
170. Stolnik, S., et al.: Long circulating microparticulate drug carriers. Adv. Drug Del. Rev. 16, 195-214 (1995).
171. Sun, R., et al.: Physical and biological characterization of superparamagnetic iron oxide- And ultrasmall superparamagnetic iron oxide-labeled cells. Invest. Radiol. 40, 504-513 (2005).
172. Sun, S. and Zeng, H.: Size-controlled synthesis of magnetite nanoparticles. J. Am. Chem. Soc. 124, 8204-8205 (2002).
173. 4 (M=Fe, Co, Mn) nanoparticles. J. Am. Chem. Soc. 126, 273-279 (2004).
174. Suslick, K.S., et al.: Sonochemical synthesis of iron colloids. J. Am. Chem. Soc. 118, 11960- 11961 (1996).
175. Suwa, T., et al.: Magnetic Resonance imaging of esophageal squamous cell carcinoma using magnetite particles coated with anti-epidermal growth factor receptor antibody. Int. J. Cancer 75, 626-634 (1998).
176. Takeda, S., et al.: Development of magnetically targeted drug delivery system using superconducting magnet. J. Magn. Magn. Mater. 311, 367-371 (2007).
177. 4 nanocrystals: spectroscopic observation of aqueous oxidation kinetics. J. Phys. Chem. B 107, 7501-7506 (2003).
178. Taupitz, M., et al.: Phase I clinical evaluation of citrate-coated monocrystalline very small superparamagnetic iron oxide particles as a new contrast medium for magnetic resonance imaging. Invest. Radiol. 39, 394-405 (2004).
179. Thorek, D.L.J., et al.: Superparamagnetic iron oxide nanoparticle probes for molecular imaging. Ann. Biomed. Eng. 34, 23-38 (2006).
180. Tiefenauer, L.X., et al.: Antibody-magnetite nanoparticles: in vitro characterization of a potential tumor-specific contrast agent for magnetic resonance imaging. Bioconjug. Chem. 4, 347-352 (1993).
181. Tiefenauer, L.X., et al.: In vivo evaluation of magnetite nanoparticles for use as a tumor contrast agent in MRI. Magn. Reson. Imaging 14, 391-402 (1996).
182. Toma, A., et al.: Monoclonal antibody A7-superparamagnetic iron oxide as contrast agent of MR imaging of rectal carcinoma. Br. J. Cancer 93, 131-136 (2005).
183. Torchilin, V.P.: Drug targeting. Eur. J. Pharm. Sci. 11(Suppl. 2), S81-S91 (2000).
184. Treleaven, J.G., et al.: Removal of neuroblastoma cells from bone marrow with monoclonal antibodies conjugated to magnetic microspheres. The Lancet 14, 70-73 (1984).
185. Treleaven, J.G.: Bone marrow purging: An appraisal of immunological and nonimmunological methods. Adv. Drug Del. Rev. 2/3, 253-269 (1988).
186. Udrea, L.E., et al.: An in vitro study of magnetic particle targeting in small blood vessels. Phys. Med. Biol. 51, 4869-4881 (2006).
187. van der Zee, J.: Heating the patient: A promising approach? Ann. Oncol. 13, 1173-1184 (2002).
188. Veintemillas-Verdaguer, S., et al.: Effect of the oxidation conditions on the maghemites production by laser pyrolysis. J. Appl. Organometal. Chem. 15, 365-372 (2001).
189. Vlahos, L., et al.: A comparative study between Gd-DTPA and oral magnetic particles (OMP) as gastrointestinal (GI) contrast agents forMRI of the abdomen.Magn. Reson. Imaging 12, 719-726 (1994).
190. Wadghiri, Y.Z., et al.: Detection of alzheimer's amyloid in transgenic mice using magnetic resonance microimaging. Magn. Reson. Med. 50, 293-302 (2003).
191. Walter, G.A., et al.: Noninvasive monitoring of stem cell transfer for muscle disorders. Magn. Reson. Med. 51, 273-277 (2004).
192. Wang, F.H., et al.: Magnetic resonance tracking of nanoparticle labelled neural stem cells in a rat's spinal cord. Nanotechnol. 17, 1911-1915 (2006).
193. Wang, J., et al.: Stepwise directing of nanocrystals to self-assemble at water/oil interfaces. Angew. Chem. Int. Ed. 45, 7963-7966 (2006).
194. Wang, X., et al.: The heating effect of magnetic fluids in an alternating magnetic field. J. Magn. Magn. Mater. 293, 334-340 (2005).
195. Wang, Y.-X.J., et al.: Superparamagnetic iron oxide contrast agents: physicochemical characteristics and applications in MR imaging. Eur. Radiol. 11, 2319-2331 (2001).
196. Wang, Y., et al.: "Pulling" nanoparticles into water: phase transfer of oleic acid stabilized monodisperse nanoparticles into aqueous solutions of α-cyclodextrin. Nano Lett. 3, 1555-1559 (2003).
197. Weissleder, R., et al.: Superparamagnetic iron oxide: pharmacokinetics and toxicity. AJR 152, 167-173 (1989).
198. Weissleder, R., et al.: Ultrasmall superparamagnetic iron oxide: characterization of a new class of contrast agents for MR imaging. Radiology 175, 489-493 (1990).
199. Weissleder, R., et al.: MR receptor imaging: ultrasmall iron oxide particles targeted to asialoglycoprotein receptors. AJR 155, 1161-1167 (1990).
200. Weissleder, R., et al.: Polyclonal human immunoglobulin G labeled with polymeric iron oxide: Antibody MR imaging. Radiology 181, 245-249 (1991).
201. Weissleder, R., et al.: Antimyosin-labeled monocrystalline iron oxide allows detection of myocardial infarct: MR antibody imaging. Radiology 182, 381-385 (1992).
202. Weissleder, R., et al.: Long-circulating iron oxides for MR imaging. Adv. Drug Del. Rev. 16, 321-334 (1995).
203. Weissleder, R., et al.: In vivo magnetic resonance imaging of transgene expression. Nat. Med. 6, 351-355 (2000).
204. Weissleder, R., et al.: Cell-specific targeting of nanoparticles by multivalent attachment of small molecules. Nat. Biotechnol. 23, 1418-1423 (2005).
205. Whitehead, R.A.: Magnetic particles for use in separations. US Patent 4, 554, 088: November 19, 1985.
206. Wondergem, J., et al.: Effects of local hyperthermia on the motor function of the rat sciatic nerve. Int. J. Radiat. Biol. 53, 429-439 (1988).
207. Wunderbaldinger, P., et al.: Crosslinked iron oxides (CLIO): A new platform for the development of targeted MR contrast agents. Acad. Radiol. 9(suppl. 2), S304-S306 (2002).
208. Xia, H., et al.: Hyperthermia combined with intra-thoracic chemotherapy and radiotherapy for malignant pleural mesothelioma. Int. J. Hyperthermia 22, 613-621 (2006).
209. 4/Au/Ag nanoparticles with tunable plasmonic properties. J. Am. Chem. Soc. 129, 8698-8699 (2007).
210. 4 nanoparticles. J. Am. Chem. Soc. 126, 11458-11459 (2004).
211. Zhang, C., et al.: Silica- And alkoxysilane-coated ultrasmall superparamagnetic iron oxide particles: A promising tool to label cells for magnetic resonance imaging. Langmuir 23, 1427-1434 (2007).
212. Zhang, Y., et al.: Surface modification of superparamagnetic magnetite nanoparticles and their intracellular uptake. Biomaterials 23, 1553-1561 (2002).
213. Zhang, Y. and Zhang, J.: Surface modification of monodisperse magnetite nanoparticles for improved intracellular uptake to breast cancer cells. J. Colloid Interface Sci. 283, 352-357 (2005).
214. Zhao, M., et al.: Non-invasive detection of apoptosis using magnetic resonance imaging and a targeted contrast agent. Nat. Med. 7, 1241-1244 (2001).
215. Zhao, M., et al.: Differential conjugation of tat peptide to superparamagnetic nanoparticles and Its effect on cellular uptake. Bioconjug. Chem. 13, 840-844 (2002).
216. Zinderman, C.E., et al.: Anaphylactoid reactions to dextran 40 and 70: reports to the United States Food and Drug Administration, 1969 to 2004. J. Vasc. Surg. 43, 1004-1009 (2006).